Clinical trials: Vascular Patients
Fabry Disease
A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
Fabry Disease is a rare blood disorder that some people are born with. People with Fabry disease have low levels of an enzyme called alpha-galactosidase A. This enzyme helps to cut down fat-like substances.
- Trial name
- NCT07187440
- Testing
- No intervention
- Where
- 18 sites in China
- Volunteers
- 200 people
- Sponsor
- Takeda
Multiple Myeloma
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Panobinostat (LBH589) is a highly potent pan-deacetylase inhibitor (pan-DACi), inclusive of HDAC6, which disrupts aggresome function, promotes accumulation of cytotoxic misfolded protein aggregates and triggers myeloma cell…
- Trial name
- PANORAMA-1 (NCT01023308)
- Testing
- Panobinostat, Bortezomib, Dexamethasone
- Where
- 210 sites in United States, Argentina and 32 more
- Volunteers
- 767 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
MK-0954E Phase III Long-Term Study in Participants With Hypertension (MK-0954E-356)
This study has two parts. In the first part, the efficacy and safety MK-0954E (losartan potassium 50 mg [L50] (+) hydrochlorothiazide 12.5 mg [H12.5] (+) amlodipine besylate 5mg [A5]) will be evaluated and compared to the…
- Trial name
- NCT01299376
- Testing
- L50/H12.5/A5, L50/H12.5
- Volunteers
- 286 people
- Sponsor
- Merck Sharp & Dohme LLC
Arteriosclerosis
Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA)
RATIONALE: Atherothrombosis is a progressive and generalized vascular disease resulting in events leading to myocardial infarction (heart attack), stroke, and vascular death.
- Trial name
- NCT00050817
- Testing
- clopidogrel (SR25990)
- Where
- 32 sites in United States, Argentina and 30 more
- Volunteers
- 15,603 people
- Sponsor
- Sanofi
Hypertension
Safety, Tolerability and Efficacy of Micardis® in Patients With Essential Hypertension
This post-marketing surveillance study was designed to supplement under conditions of normal clinical practice the data on the safety, tolerability and efficacy of Micardis® collected during the clinical studies.
- Trial name
- NCT02176850
- Testing
- Micardis®
- Volunteers
- 19,870 people
- Sponsor
- Boehringer Ingelheim
Multiple Myeloma, Newly Diagnosed
Non-interventional Study to Evaluate Patient and Healthcare Provider Satisfaction of Daratumumab Use in the Treatment of First-line Daratumumab, Lenalidomide, Dexamethasone (DRd) Multiple Myeloma Patients in Germany Depending on Application Route (sc or iv)
MYLENE is a prospective, multicenter, NIS to evaluate the patient and HCP satisfaction of sc and iv application of daratumumab in routine clinical practice in Germany.
- Conditions
- Multiple Myeloma, Newly Diagnosed, Transplant Ineligible, Patient Satisfaction
- Trial name
- MYLENE (NCT05284591)
- Testing
- Daratumumab
- Where
- Germany
- Volunteers
- 96 people
- Sponsor
- iOMEDICO AG
Multiple Myeloma
Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma
This is a phase 1b, open-label, dose-escalation study of STI-1492 administered by a single intravenous infusion in subjects with relapsed or refractory multiple myeloma.
- Trial name
- NCT05007418
- Testing
- STI-1492
- Where
- 3 sites in United States
- Volunteers
- 54 people
- Sponsor
- Sorrento Therapeutics, Inc.
Venous Thromboembolism
Treatment of Venous Thromboembolism in Real-Life Patients
In a population of patients with venous thromboembolism and treated with oral anticoagulants (OAC) in routine clinical practice in Denmark this study will describe patients treated with each OAC
- Trial name
- NCT03087474
- Testing
- Non-Interventional
- Volunteers
- 89,383 people
- Sponsor
- Bristol-Myers Squibb
Carotid Atherosclerosis, Carotid Artery Disease
ACCULINK for Revascularization of Carotids in High Risk Patients "The ARCHeR Trial"
1. To evaluate the safety and efficacy of the over-the-wire (OTW) ACCULINK (tm) System in patients deemed to be either at high risk or unsuitable for carotid endarterectomy (CEA) 2.
- Trial name
- NCT00180518
- Testing
- Over-the-wire & Rapid Exchange ACCULINK (tm) Carotid Stent & ACCUNET (tm) embolic protection system
- Volunteers
- 581 people
- Sponsor
- Abbott Medical Devices
Hypertension, Pulmonary
EXPERT, EXPosurE Registry RiociguaT in Patients With Pulmonary Hypertension
In accordance with the regulatory guidance this registry has been designed to collect information about the long-term safety of Adempas in real clinical practice outside the regulated environment of a controlled clinical study.
- Trial name
- EXPERT (NCT02092818)
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 28 sites in Argentina, Australia and 26 more
- Volunteers
- 1,316 people
- Sponsor
- Bayer
End Stage Renal Disease
HeRO Vascular Access Device Post Market Procedural Survey Protocol
Post market observational survey of a vascular access device for access-challenged patients. Data collection efforts focused on patient medical and access history and implant procedure results.
- Trial name
- PPS (NCT00889291)
- Volunteers
- 77 people
- Sponsor
- Merit Medical Systems, Inc.
Raynaud's Phenomenon
Dose Response to Topical Glyceryl Trinitrate in Patients With Raynaud's Phenomenon
The purpose of this study is to evaluate the blood flow response to topical Glyceryl Trinitrate when applied to the skin of patient's fingers with Raynaud's Phenomenon.
- Trial name
- NCT00700518
- Testing
- Glyceryl Trinitrate
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Procris Pharmaceuticals
Diabetic Foot Ulcer
FeetSee Thermal Images Collection Protocol in Diabetes Patients
Diabetic foot ulcers (DFUs) are a major cause of morbidity, lower-extremity amputation and healthcare costs in people with diabetes.
- Trial name
- NCT07300163
- Testing
- FeetSee thermal camera
- Where
- 4 sites in Lithuania, United Kingdom
- Volunteers
- 100 people
- Sponsor
- Diabetis JSC
Venous Thromboembolism
Dose-confirmatory Bridging Study in Total Hip Replacement
The objective of this dose-confirmatory bridging study is to investigate the safety and efficacy of rivaroxaban 5 to 10 mg once-daily (od) dosing in the prevention of venous thromboembolism (VTE) in Japanese patients undergoing…
- Trial name
- NCT01205932
- Testing
- Rivaroxaban (BAY59-7939), Enoxaparin
- Where
- 41 sites in Japan
- Volunteers
- 402 people
- Sponsor
- Bayer
Kawasaki Disease
Study of Efficacy and Safety of Canakinumab in Pediatric Patients With Kawasaki Disease
The purpose of this trial is to evaluate whether, in Intravenous Immunoglobulin-naïve or refractory patients diagnosed with active Kawasaki disease, administration of canakinumab controls fever and acute phase reactants.
- Trial name
- NCT02980263
- Testing
- Canakinumab
- Sponsor
- Novartis Pharmaceuticals
Vascular Ehlers-Danlos Syndrome
Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in Patients With Vascular Ehlers-Danlos Syndrome
This is a prospective, Phase 3, randomized, double-blind, placebo-controlled efficacy study to evaluate celiprolol in patients genetically confirmed as COL3A1-positive vEDS using a decentralized clinical trial design.
- Trial name
- DiSCOVER (NCT05432466)
- Testing
- ACER-002 (celiprolol) 200 mg BID
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Acer Therapeutics Inc.
Alzheimer's Disease, Lewy Body Dementia
Pulsed Electromagnetic Field Treatment With Dementia Patients
An open label pilot study in mild to moderate AD/ADRD patients to assess the effects of treatment with ECHS AD/ADRD pulsed electromagnetic treatment device on disease progression. Enrolled patients will receive active devices.
- Conditions
- Alzheimer's Disease, Lewy Body Dementia, Vascular Dementia
- Trial name
- NCT06862557
- Testing
- ECHS AD Device
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Herrick Medical LLC
Central Retinal Vein Occlusion
Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO)
Provide efficacy and safety data on intravitreal injections of ranibizumab 0.5 mg in patients with visual impairment due to macular edema secondary to CRVO
- Trial name
- Camellia (NCT01976312)
- Testing
- Ranibizumab 0.5 mg
- Where
- 34 sites in China, Hong Kong and 5 more
- Volunteers
- 252 people
- Sponsor
- Novartis Pharmaceuticals
Prevention of Atherothrombotic Events, Coronary Artery Disease (CAD)
Study to Learn More About the Safety and Effectiveness of Rivaroxaban (Xarelto) When Given Together With Acetylsalicylic Acid to Indian People With Narrowing of the Arteries of the Heart (CAD) and/or With Reduced Blood Flow in the Arteries of the Legs and Arms With Symptoms (Symptomatic PAD)
This is an observational study in which data from Indian people with coronary artery disease and / or symptomatic peripheral artery disease who will be receiving the drug rivaroxaban (Xarelto) are studied.
- Conditions
- Prevention of Atherothrombotic Events, Coronary Artery Disease (CAD), Symptomatic Peripheral Artery Disease (Symptomatic PAD)
- Trial name
- NCT04298567
- Testing
- Rivaroxaban (Xarelto,Bay 59-7939), Acetylsalicylic acid(ASA)
- Where
- India
- Volunteers
- 300 people
- Sponsor
- Bayer
Left Ventricular Dysfunction, Coronary Artery Disease
Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function
The purpose of this study is to assess if using the Impella® CP (or Impella® 2.5) device during high-risk PCI in patients with reduced left-sided heart function will result in an improvement in symptoms, heart function and health…
- Trial name
- PROTECT IV (NCT04763200)
- Testing
- Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®, IABP Intra-aortic balloon pump
- Where
- 110 sites in United States, Canada and 5 more
- Volunteers
- 1,252 people
- Sponsor
- Abiomed Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.